Home » Stocks » HOOKIPA Pharma

HOOKIPA Pharma Inc. (HOOK)

Stock Price: $9.58 USD -0.19 (-1.94%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 245.77M
Revenue (ttm) 16.04M
Net Income (ttm) -39.65M
Shares Out 21.83M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $9.58
Previous Close $9.77
Change ($) -0.19
Change (%) -1.94%
Day's Open 10.01
Day's Range 9.53 - 10.01
Day's Volume 45,408
52-Week Range 5.80 - 14.37

More Stats

Market Cap 245.77M
Enterprise Value 162.97M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 21.83M
Float 11.80M
EPS (basic) -1.43
EPS (diluted) -1.55
FCF / Share -1.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 873,950
Short Ratio 10.19
Short % of Float 7.41%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.33
PB Ratio 2.41
Revenue 16.04M
Operating Income -48.49M
Net Income -39.65M
Free Cash Flow -38.60M
Net Cash 82.80M
Net Cash / Share 3.23
Gross Margin -214.32%
Operating Margin -302.34%
Profit Margin -247.20%
FCF Margin -240.69%
ROA -20.11%
ROE -33.05%
ROIC -141.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(85.28% upside)
Current: $9.58
Target: 17.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth56.53%--
Gross Profit11.947.63-
Operating Income-51.09-21.18-14.16
Net Income-43.04-16.24-12.72
Shares Outstanding17.860.910.91
Earnings Per Share-2.41-17.76-13.95
Operating Cash Flow-41.73-15.00-11.91
Capital Expenditures-2.00-2.15-1.30
Free Cash Flow-43.73-17.15-13.21
Cash & Equivalents11348.5861.36
Total Debt10.604.393.74
Net Cash / Debt10344.1957.62
Book Value118-60.38-42.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name HOOKIPA Pharma Inc.
Country United States
Employees 85
CEO Jörn Aldag

Stock Information

Ticker Symbol HOOK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HOOK
IPO Date April 18, 2019


HOOKIPA Pharma, a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.